These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17085980)

  • 1. Achievement of national cholesterol education program goals by patients with dyslipidemia in rural ambulatory care settings.
    Qayyum R; Chattha AA; Bhullar N; Katsetos M; Schulman P
    Prev Cardiol; 2006; 9(4):192-7. PubMed ID: 17085980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
    Nichols GA; Ambegaonkar BM; Sazonov V; Brown JB
    Am J Cardiol; 2009 Dec; 104(12):1689-94. PubMed ID: 19962476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital.
    Sangsawang T; Sriwijitkamol A
    Vasc Health Risk Manag; 2015; 11():563-7. PubMed ID: 26604773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study.
    Diamantopoulos EJ; Athyros VG; Yfanti GK; Migdalis EN; Elisaf M; Vardas PE; Manolis AS; Karamitsos DT; Ganotakis ES; Hatseras D;
    Angiology; 2005; 56(6):731-41. PubMed ID: 16327950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving low-density lipoprotein cholesterol treatment goals among dyslipidemic individuals in the Levant: the CEntralized Pan-Levant survey on tHE Undertreatment of hypercholeSterolemia (CEPHEUS) study.
    Hammoudeh AJ; Echtay A; Ghanem GY; Haddad J;
    Curr Med Res Opin; 2014 Oct; 30(10):1957-65. PubMed ID: 24889279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study.
    Villeneuve J; Genest J; Blais L; Vanier MC; Lamarre D; Fredette M; Lussier MT; Perreault S; Hudon E; Berbiche D; Lalonde L
    CMAJ; 2010 Mar; 182(5):447-55. PubMed ID: 20212029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25 years of follow-up data.
    Premstaller M; Perren M; Koçack K; Arranto C; Favre G; Lohri A; Gerull S; Passweg JR; Halter JP; Leuppi-Taegtmeyer AB
    J Clin Lipidol; 2018; 12(2):464-480.e3. PubMed ID: 29310991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy.
    Zhao W; Zheng XL; Jiang ZN; Liao XB; Zhao SP
    Int J Cardiol; 2017 Dec; 248():355-360. PubMed ID: 28689987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study.
    Khovidhunkit W; Silaruks S; Chaithiraphan V; Ongphiphadhanakul B; Sritara P; Nimitphong H; Benjanuwattra T; Ambegaonkar BM
    Angiology; 2012 Oct; 63(7):528-34. PubMed ID: 22222187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia.
    Chopra I; Kamal KM
    Hosp Pract (1995); 2014 Apr; 42(2):77-88. PubMed ID: 24769787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease.
    Poussa H; Strandberg TE; Tikkanen I; Kauhanen P; Lepäntalo M
    Scand Cardiovasc J; 2007 Jun; 41(3):138-41. PubMed ID: 17487761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of a pharmacy care management program for veterans with dyslipidemia.
    Smith MC; Boldt AS; Walston CM; Zillich AJ
    Pharmacotherapy; 2013 Jul; 33(7):736-43. PubMed ID: 23625745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.